← All trials
NCT04529005
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2020
- Primary completion
- Jul 1, 2021
- Completion date
- Jul 1, 2021
- First posted
- Aug 27, 2020
- Last posted
- Aug 27, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Illinois at ChicagoLead sponsor
- La Jolla Pharmaceutical CompanyCollaborator
- University of Illinois at ChicagoReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.